Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1978 1
1980 1
1982 2
1983 2
1984 1
1985 4
1986 5
1987 2
1988 3
1989 1
1990 2
1991 4
1993 2
1994 2
1995 7
1996 6
1997 3
1998 11
1999 10
2000 11
2001 9
2002 12
2003 10
2004 5
2005 11
2006 9
2007 9
2008 8
2009 19
2010 16
2011 12
2012 17
2013 19
2014 15
2015 28
2016 18
2017 13
2018 17
2019 15
2020 24
2021 24
2022 24
2023 4
Text availability
Article attribute
Article type
Publication date

Search Results

373 results
Results by year
Filters applied: . Clear all
Page 1
Once-Weekly Semaglutide in Adults with Overweight or Obesity.
Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF; STEP 1 Study Group. Wilding JPH, et al. Among authors: wharton s. N Engl J Med. 2021 Mar 18;384(11):989-1002. doi: 10.1056/NEJMoa2032183. Epub 2021 Feb 10. N Engl J Med. 2021. PMID: 33567185 Clinical Trial.
Tirzepatide Once Weekly for the Treatment of Obesity.
Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A; SURMOUNT-1 Investigators. Jastreboff AM, et al. Among authors: wharton s. N Engl J Med. 2022 Jul 21;387(3):205-216. doi: 10.1056/NEJMoa2206038. Epub 2022 Jun 4. N Engl J Med. 2022. PMID: 35658024 Clinical Trial.
Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial.
O'Neil PM, Birkenfeld AL, McGowan B, Mosenzon O, Pedersen SD, Wharton S, Carson CG, Jepsen CH, Kabisch M, Wilding JPH. O'Neil PM, et al. Among authors: wharton s. Lancet. 2018 Aug 25;392(10148):637-649. doi: 10.1016/S0140-6736(18)31773-2. Epub 2018 Aug 16. Lancet. 2018. PMID: 30122305 Clinical Trial.
Obesity in adults: a clinical practice guideline.
Wharton S, Lau DCW, Vallis M, Sharma AM, Biertho L, Campbell-Scherer D, Adamo K, Alberga A, Bell R, Boulé N, Boyling E, Brown J, Calam B, Clarke C, Crowshoe L, Divalentino D, Forhan M, Freedhoff Y, Gagner M, Glazer S, Grand C, Green M, Hahn M, Hawa R, Henderson R, Hong D, Hung P, Janssen I, Jacklin K, Johnson-Stoklossa C, Kemp A, Kirk S, Kuk J, Langlois MF, Lear S, McInnes A, Macklin D, Naji L, Manjoo P, Morin MP, Nerenberg K, Patton I, Pedersen S, Pereira L, Piccinini-Vallis H, Poddar M, Poirier P, Prud'homme D, Salas XR, Rueda-Clausen C, Russell-Mayhew S, Shiau J, Sherifali D, Sievenpiper J, Sockalingam S, Taylor V, Toth E, Twells L, Tytus R, Walji S, Walker L, Wicklum S. Wharton S, et al. CMAJ. 2020 Aug 4;192(31):E875-E891. doi: 10.1503/cmaj.191707. CMAJ. 2020. PMID: 32753461 Free PMC article. No abstract available.
Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5.
Kushner RF, Calanna S, Davies M, Dicker D, Garvey WT, Goldman B, Lingvay I, Thomsen M, Wadden TA, Wharton S, Wilding JPH, Rubino D. Kushner RF, et al. Among authors: wharton s. Obesity (Silver Spring). 2020 Jun;28(6):1050-1061. doi: 10.1002/oby.22794. Obesity (Silver Spring). 2020. PMID: 32441473 Free PMC article. Clinical Trial.
Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension.
Wilding JPH, Batterham RL, Davies M, Van Gaal LF, Kandler K, Konakli K, Lingvay I, McGowan BM, Oral TK, Rosenstock J, Wadden TA, Wharton S, Yokote K, Kushner RF; STEP 1 Study Group. Wilding JPH, et al. Among authors: wharton s. Diabetes Obes Metab. 2022 Aug;24(8):1553-1564. doi: 10.1111/dom.14725. Epub 2022 May 19. Diabetes Obes Metab. 2022. PMID: 35441470 Free PMC article. Clinical Trial.
L’obésité chez l’adulte : ligne directrice de pratique clinique.
Wharton S, Lau DCW, Vallis M, Sharma AM, Biertho L, Campbell-Scherer D, Adamo K, Alberga A, Bell R, Boulé N, Boyling E, Brown J, Calam B, Clarke C, Crowshoe L, Divalentino D, Forhan M, Freedhoff Y, Gagner M, Glazer S, Grand C, Green M, Hahn M, Hawa R, Henderson R, Hong D, Hung P, Janssen I, Jacklin K, Johnson-Stoklossa C, Kemp A, Kirk S, Kuk J, Langlois MF, Lear S, McInnes A, Macklin D, Naji L, Manjoo P, Morin MP, Nerenberg K, Patton I, Pedersen S, Pereira L, Piccinini-Vallis H, Poddar M, Poirier P, Prud'homme D, Salas XR, Rueda-Clausen C, Russell-Mayhew S, Shiau J, Sherifali D, Sievenpiper J, Sockalingam S, Taylor V, Toth E, Twells L, Tytus R, Walji S, Walker L, Wicklum S. Wharton S, et al. CMAJ. 2020 Dec 7;192(49):E1757-E1775. doi: 10.1503/cmaj.191707-f. CMAJ. 2020. PMID: 33288515 Free PMC article. French. No abstract available.
Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial.
Garvey WT, Batterham RL, Bhatta M, Buscemi S, Christensen LN, Frias JP, Jódar E, Kandler K, Rigas G, Wadden TA, Wharton S; STEP 5 Study Group. Garvey WT, et al. Among authors: wharton s. Nat Med. 2022 Oct;28(10):2083-2091. doi: 10.1038/s41591-022-02026-4. Epub 2022 Oct 10. Nat Med. 2022. PMID: 36216945 Free PMC article. Clinical Trial.
373 results